Literature DB >> 12712490

Patients' willingness to participate in symptom-related and disease-modifying research: results of a research screening initiative in a palliative care clinic.

Roxane Crowley1, David Casarett.   

Abstract

BACKGROUND: The growth of cancer symptom management research has been limited by challenges of slow recruitment and under-enrollment. One potential solution to this problem is the use of screening questions that identify patients who are interested in participating in research. The goal of this study was to evaluate this strategy in patients with cancer.
METHODS: Two screening questions (for symptom management research and disease-modifying research) were integrated into the intake process of the palliative care clinic of an urban Veteran's Administration medical center. A chart review was conducted to extract patients' reported willingness to be recruited for research, explanations for their responses, demographic data, Memorial Symptom Assessment Scale Global Distress Index (GDI) subscale scores, and Eastern Cooperative Oncology Group performance score.
RESULTS: Charts were reviewed for the first 100 patients seen for a palliative care clinic visit, 86 of whom had cancer. Patients were less likely to be interested in symptom-related research than in disease-modifying research (32 of 86 [37%] vs. 46 of 86 [54%]; sign test, P = 0.009). Patients' interest in each type of research was associated moderately (kappa = 0.41; P < 0.001). Independent predictors of interest in symptom management research included younger age, white race, and a lower GDI symptom distress score. Independent predictors of interest in disease-modifying research included only younger age and white race.
CONCLUSIONS: Screening questions may be useful in identifying patients who are willing to be recruited for research. However, further study is needed to evaluate this process in other populations, as well as to determine whether screening questions introduce selection bias in the recruitment process.

Entities:  

Mesh:

Year:  2003        PMID: 12712490     DOI: 10.1002/cncr.11329

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Ethical challenges and solutions regarding delirium studies in palliative care.

Authors:  Lisa Sweet; Dimitrios Adamis; David J Meagher; Daniel Davis; David C Currow; Shirley H Bush; Christopher Barnes; Michael Hartwick; Meera Agar; Jessica Simon; William Breitbart; Neil MacDonald; Peter G Lawlor
Journal:  J Pain Symptom Manage       Date:  2013-12-31       Impact factor: 3.612

2.  Methodological challenges in conducting a multi-site randomized clinical trial of massage therapy in hospice.

Authors:  Jean Kutner; Marlaine Smith; Karen Mellis; Sue Felton; Traci Yamashita; Lisa Corbin
Journal:  J Palliat Med       Date:  2010-06       Impact factor: 2.947

3.  Recruitment strategies and rates of a multi-site behavioral intervention for adolescents and young adults with cancer.

Authors:  Verna L Hendricks-Ferguson; Brooke O Cherven; Debra S Burns; Sharron L Docherty; Celeste R Phillips-Salimi; Lona Roll; Kristin A Stegenga; Molly Donovan Stickler; Joan E Haase
Journal:  J Pediatr Health Care       Date:  2012-06-02       Impact factor: 1.812

4.  Sampling in population-based cancer caregivers research.

Authors:  Youngmee Kim; Deborah A Kashy; Chiew Kwei Kaw; Tenbroeck Smith; Rachel L Spillers
Journal:  Qual Life Res       Date:  2009-08-05       Impact factor: 4.147

5.  Ethical conduct of palliative care research: enhancing communication between investigators and institutional review boards.

Authors:  Amy P Abernethy; Warren H Capell; Noreen M Aziz; Christine Ritchie; Maryjo Prince-Paul; Rachael E Bennett; Jean S Kutner
Journal:  J Pain Symptom Manage       Date:  2014-05-28       Impact factor: 3.612

Review 6.  Challenges to and lessons learned from conducting palliative care research.

Authors:  Ann M O'Mara; Diane St Germain; Betty Ferrell; Tami Bornemann
Journal:  J Pain Symptom Manage       Date:  2008-08-19       Impact factor: 3.612

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.